(Q37000746)

17 August 2017

1 reference

title

The importance of treating multiple cardiometabolic risk factors in patients with Type 2 diabetes (English)

1 reference

17 August 2017

0 references

Dimitri P Mikhailidis

series ordinal

1

object named as

Dimitri P Mikhailidis

1 reference

17 August 2017

Martin Press

2

1 reference

17 August 2017

language of work or name

English

0 references

publication date

1 December 2007

1 reference

Expert Opinion on Pharmacotherapy

17 August 2017

published in

1 reference

17 August 2017

volume

8

1 reference

17 August 2017

issue

17

1 reference

17 August 2017

page(s)

3009-3020

1 reference

Primary prevention of cardiovascular diseases in people with diabetes mellitus: a scientific statement from the American Heart Association and the American Diabetes Association

17 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.17.3009

Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.17.3009

Prognostic significance of silent coronary artery disease in type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.17.3009

Do atherosclerosis and type 2 diabetes share a common inflammatory basis?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.17.3009

Adipose expression of tumor necrosis factor-alpha: direct role in obesity-linked insulin resistance

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.17.3009

The association between abdominal visceral fat and carotid stiffness is mediated by circulating inflammatory markers in uncomplicated type 2 diabetes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.17.3009

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.17.3009

Health consequences of visceral obesity

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.17.3009

Waist circumference and abdominal sagittal diameter: best simple anthropometric indexes of abdominal visceral adipose tissue accumulation and related cardiovascular risk in men and women.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.17.3009

Adipose tissue as an endocrine organ

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.17.3009

Leptin: a promising therapeutic target with pleiotropic action besides body weight regulation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.17.3009

Plasma leptin and the risk of cardiovascular disease in the west of Scotland coronary prevention study (WOSCOPS).

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.17.3009

Leptinemia is not a risk factor for ischemic heart disease in men. Prospective results from the Quebec Cardiovascular Study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.17.3009

Adiponectin: more than just another fat cell hormone?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.17.3009

Elevated levels of acute-phase proteins and plasminogen activator inhibitor-1 predict the development of type 2 diabetes: the insulin resistance atherosclerosis study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.17.3009

Inflammation, obesity, stress and coronary heart disease: is interleukin-6 the link?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.17.3009

Profiling gene transcription in vivo reveals adipose tissue as an immediate target of tumor necrosis factor-alpha: implications for insulin resistance

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.17.3009

21 January 2018

The metabolic syndrome

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.17.3009

Comparison of C-reactive protein and low-density lipoprotein cholesterol levels in the prediction of first cardiovascular events

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.17.3009

C-reactive protein and myocardial infarction

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.17.3009

C-reactive protein, the metabolic syndrome, and prediction of cardiovascular events in the Framingham Offspring Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.17.3009

Obesity is a major determinant of the association of C-reactive protein levels and the metabolic syndrome in type 2 diabetes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.17.3009

Cardiovascular disease in U.S. patients with metabolic syndrome, diabetes, and elevated C-reactive protein

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.17.3009

Value of serum glycated albumin and high-sensitivity C-reactive protein levels in the prediction of presence of coronary artery disease in patients with type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.17.3009

Markers of inflammation and cardiovascular disease: application to clinical and public health practice: A statement for healthcare professionals from the Centers for Disease Control and Prevention and the American Heart Association

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.17.3009

C-reactive protein: risk marker or mediator in atherothrombosis?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.17.3009

Effects of lifestyle modifications on C-reactive protein: contribution of weight loss and improved aerobic capacity

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.17.3009

The effect of weight loss on C-reactive protein: a systematic review

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.17.3009

Treating dyslipidaemia in non-insulin-dependent diabetes mellitus -- a special reference to statins

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.17.3009

Effect of statin therapy on C-reactive protein levels: the pravastatin inflammation/CRP evaluation (PRINCE): a randomized trial and cohort study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.17.3009

C-reactive protein levels and outcomes after statin therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.17.3009

Statin therapy, LDL cholesterol, C-reactive protein, and coronary artery disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.17.3009

Low-density lipoprotein-dependent and -independent effects of cholesterol-lowering therapies on C-reactive protein: a meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.17.3009

Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomised controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.17.3009

Diabetes, plasma insulin, and cardiovascular disease: subgroup analysis from the Department of Veterans Affairs high-density lipoprotein intervention trial (VA-HIT).

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.17.3009

Effect of fenofibrate on serum inflammatory markers in patients with high triglyceride values

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.17.3009

Effect of ciprofibrate on C-reactive protein and fibrinogen levels

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.17.3009

Benefits of niacin in patients with versus without the metabolic syndrome and healed myocardial infarction (from the Coronary Drug Project).

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.17.3009

A community-based, randomized trial of ezetimibe added to statin therapy to attain NCEP ATP III goals for LDL cholesterol in hypercholesterolemic patients: the ezetimibe add-on to statin for effectiveness (EASE) trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.17.3009

Meta-analysis of the cholesterol-lowering effect of ezetimibe added to ongoing statin therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.17.3009

Intensive Diabetes Treatment and Cardiovascular Disease in Patients with Type 1 Diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.17.3009

Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.17.3009

Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.17.3009

Antiatherogenic effect of pioglitazone in type 2 diabetic patients irrespective of the responsiveness to its antidiabetic effect

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.17.3009

Anti-inflammatory effects of short-term pioglitazone therapy in men with advanced diabetic nephropathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.17.3009

Metabolic effects of pioglitazone in combination with insulin in patients with type 2 diabetes mellitus whose disease is not adequately controlled with insulin therapy: results of a six-month, randomized, double-blind, prospective, multicenter, para

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.17.3009

Differential effects of rosiglitazone and insulin glargine on inflammatory markers, glycemic control, and lipids in type 2 diabetes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.17.3009

Rosiglitazone increases LDL particle size and buoyancy and decreases C-reactive protein in patients with type 2 diabetes on statin therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.17.3009

Effect of Rosiglitazone on the Risk of Myocardial Infarction and Death from Cardiovascular Causes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.17.3009

Irbesartan treatment reduces biomarkers of inflammatory activity in patients with type 2 diabetes and microalbuminuria: an IRMA 2 substudy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.17.3009

Metabolic effects of carvedilol vs metoprolol in patients with type 2 diabetes mellitus and hypertension: a randomized controlled trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.17.3009

Effect of sibutramine on weight maintenance after weight loss: a randomised trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.17.3009

Effect of orlistat, micronised fenofibrate and their combination on metabolic parameters in overweight and obese patients with the metabolic syndrome: the FenOrli study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.17.3009

Effect of rimonabant, a cannabinoid-1 receptor blocker, on weight and cardiometabolic risk factors in overweight or obese patients: RIO-North America: a randomized controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.17.3009

Effects of the cannabinoid-1 receptor blocker rimonabant on weight reduction and cardiovascular risk factors in overweight patients: 1-year experience from the RIO-Europe study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.17.3009

Effects of rimonabant on metabolic risk factors in overweight patients with dyslipidemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.17.3009

Rimonabant: endocannabinoid inhibition for the metabolic syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.17.3009

The role of endocannabinoid system blockade in the treatment of the metabolic syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.17.3009

Multifactorial intervention and cardiovascular disease in patients with type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.17.3009

Preventing type 2 diabetes in high risk patients: an overview of lifestyle and pharmacological measures.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.17.3009

XENical in the prevention of diabetes in obese subjects (XENDOS) study: a randomized study of orlistat as an adjunct to lifestyle changes for the prevention of type 2 diabetes in obese patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.17.3009

CDC/AHA Workshop on Markers of Inflammation and Cardiovascular Disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.17.3009

10.1517/14656566.8.17.3009

21 January 2018

Identifiers

DOI

1 reference

17 August 2017

1 reference